ERBB2 and hematologic disorder: Tebotelimab (MGD013): belongs to bispecific moAb targeting both LAG-3 and PD-1 and it was tested in the phase I clinical trial alone or in combination with margetuximab (an anti-HER2 mAb with higher binding activity for activating Fcγ receptor CD16A and decreased affinity for inhibitory CD32B) in case of HER2 expression in advanced or metastatic solid tumors or hematologic malignancies [15].